3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
72
Breast Neoplasms
9
Neoplasm Metastasis
8
Prostatic Neoplasms, Castration-Resistant
6
Neoplasms
5
Metastatic Castration-resistant Prostate Cancer
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Prostate Cancer Metastatic
3
Metastatic Castration Resistant Prostate Cancer
3
Bulbo-Spinal Atrophy, X-Linked
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Metastatic Hormone Sensitive Prostate Cancer
2
Melanoma
2
mCRPC
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Ureteral Diseases
1
Solid Tumours
1
Small Cell Lung Carcinoma
1
Seizures
1
Salivary Cancer
1
Recurrent Endometrial Endometrioid Adenocarcinoma
1
Pancreatic Neoplasms
1
Non-metastatic, Hormone naïve Prostate Cancer
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Squamous Cell
1
Metastatic Progressive Castration-resistant Prostate Cancer
1
Interventions
fludarabine phosphate
43
Whole-Body Irradiation
36
Mycophenolic Acid
36
Peripheral Blood Stem Cell Transplantation
31
Cyclophosphamide
31
Tacrolimus
28
Busulfan
22
Antilymphocyte Serum
21
Cyclosporine
19
fludarabine
17
ruxolitinib
16
Melphalan
16
Methotrexate
15
Cytarabine
12
thymoglobulin
9
Sirolimus
9
Etoposide
9
Granulocyte Colony-Stimulating Factor
8
Filgrastim
8
Cyclosporins
8
Radiotherapy
7
Cord Blood Stem Cell Transplantation
7
Rituximab
6
Alemtuzumab
6
merphos
5
Stem Cell Transplantation
5
Flow Cytometry
5
Azacitidine
5
sargramostim
4
ponatinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Myeloproliferative Disorders
×
enzalutamide
×
Clear all
No trials found.